Other factors, including increases in EGFR or ALK gene copy numbers, MET overexpression, and elevated KRAS, MET, and ERBB levels following cetuximab therapy, have been linked to CRC progression and deserve further investigation [37–39]. Here, ALK is linked to colorectal carcinoma.